While oncology remains one of the hottest areas in clinical research, clinical trials for evaluating cancer therapies can present some unique challenges. In particular, complex therapeutic designs and data analysis obstacles often create difficulties in objectively assessing tumor response.
To help address these challenges, standardized criteria (RECIST — Response Evaluation Criteria in Solid Tumors) have been developed and accepted as the primary method for categorizing tumor response.
In this presentation, you’ll discover how specialized, interactive visualizations can leverage these analysis guidelines to help you more effectively evaluate early efficacy and safety signals in oncology therapeutic studies. Specifically, you will learn:
- How lesion response analysis and the application of RECIST evaluation guidelines can be streamlined through highly visual, integrated reports.
- Why patient-level summary analyses are so critical to early efficacy endpoint detection.
- How the ability to filter by subject dramatically enhances the effectiveness of key clinical visualizations, including swimmer plots, waterfall plots, forest plots and spider plots.